Inclusion Criteria:

Each patient must meet all of the following inclusion criteria to be enrolled in the
study:

1. Male or female patients 18 years or older

2. Eastern Cooperative Oncology Group performance status 0-2

3. A diagnosis of a nonhematologic malignancy for which standard treatment is no longer
effective. In the expanded cohort, enrollment will be limited to patients with a
diagnosis of NSCLC, head and neck cancer (squamous cell cancer), soft tissue sarcoma,
or prostate cancer

4. Suitable venous access PK and pharmacodynamic evaluations

5. Female patients who are post menopausal, surgically sterile, or agree to practice 2
effective methods of contraception or abstain from heterosexual intercourse

Male patients who agree to to practice 2 effective methods of contraception or
abstain from heterosexual intercourse.

6. Voluntary written consent must be obtained

7. Adequate clinical laboratory values during the screening period

Exclusion Criteria:

Patients meeting any of the following exclusion criteria are not to be enrolled in the
study:

1. Peripheral neuropathy ≥Grade 2

2. Female patients who are lactating or have a positive serum pregnancy test during the
screening period

3. Major surgery within 14 days before the first dose of treatment

4. Infection requiring systemic antibiotic therapy or other serious infection within 14
days before the first dose of study treatment

5. Life-threatening illness unrelated to cancer

6. Diarrhea >Grade 1 based on the NCI CTCAE categorization

7. Systemic antineoplastic therapy / or radiotherapy within 21 days before the first
dose of study treatment

8. Systemic treatment with prohibited medications

9. Patient has symptomatic brain metastasis

10. Evidence of current uncontrolled cardiovascular conditions, including cardiac
arrhythmias, congestive heart failure (CHF), angina, or myocardial infarction within
the past 6 months

11. QTc >470 milliseconds (msec) on a 12-lead electrocardiogram (ECG) obtained during the
screening period

12. Known human immunodeficiency virus (HIV), hepatitis B and hepatitis C positive

13. Any serious medical or psychiatric illness that could, in the investigator's opinion,
potentially interfere with the completion of treatment according to this protocol

14. Treatment with any investigational products within 28 days before the first dose of
study treatment